Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 156

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 156
---
, and will serve as an External Director
under the Companies Law for a 3-year term. Dr. Alpert is currently the principle of SFADC LLC (aka SFA Regulatory, LLC) since 2019, a
one-person firm focused on the strategies needed to place medical devices and other medical products into the global market. She was a
Corporate Senior Vice President for Global Regulatory at Medtronic, Inc. and prior to that VP Regulatory Science at C.R. Bard, Inc. She
previously worked at the U.S. FDA where she held a variety of management positions in the centers dealing with drugs, devices and radiological
health, and foods. She was Director of the Office of Device Evaluation from 1993-1999. Dr. Alpert is a microbiologist and pediatrician
with a specialty in infectious diseases. She completed her undergraduate degree at Barnard College, Columbia University in New York City,
holds a master’s degree and Ph.D. in Biomedical Sciences from New York University and a medical degree from the University of Miami
(Florida). Dr. Alpert is a member of several non-profit and for-profit boards.

Family Relationships

There are no family relationships
between any members of our executive management and our directors.

Arrangements for Election of Directors and Members of Management

There
are no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our executive management
or our directors were selected. See “Related Party Transactions” for additional information.

Compensation

The following table presents
in the aggregate all compensation we paid to all of our directors and senior management as a group for the year ended December 31, 2024.
The table does not include any amounts we paid to reimburse any of such persons for costs incurred in providing us with services during
this period.

All amounts reported in the
table below reflect our cost, in thousands of U.S. dollars. Amounts paid in NIS are translated into U.S. dollars at the rate of NIS 3.67
= U.S. $1.00, based on the average representative rate of exchange between the NIS and the U.S. dollar as reported by the Bank of Israel
during such period of time.

|                                                                                                     |     | Salary, bonuses and Related Benefits |         |     | Pension, Retirement and Other Similar Benefits |   |     | Share Based     
 Compensation(1) |   |
|:----------------------------------------------------------------------------------------------------|:----|:-------------------------------------|